Respira Therapeutics, Inc.
Clinical trials sponsored by Respira Therapeutics, Inc., explained in plain language.
-
New inhaled treatment shows promise for rare lung condition
Symptom relief CompletedThis study tested an inhaled medication called RT234 in 14 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. The goal was to see if the drug could lower lung blood pressure and improve blood flow. Parti…
Phase: PHASE2 • Sponsor: Respira Therapeutics, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:01 UTC
-
New drug shows promise for easier breathing during exercise in PAH patients
Symptom relief CompletedThis study looked at whether a single dose of an inhaled drug called RT234 can safely help people with pulmonary arterial hypertension (PAH) exercise longer and feel less short of breath. 42 adults with PAH took the drug and then did exercise tests. The main goals were to check s…
Phase: PHASE2 • Sponsor: Respira Therapeutics, Inc. • Aim: Symptom relief
Last updated May 13, 2026 16:02 UTC
-
Healthy volunteers test new inhaled drug for lung condition
Knowledge-focused CompletedThis early-stage study tested the safety of an inhaled drug called RT234 in 31 healthy adults aged 18 to 45. Researchers measured side effects and how the drug moves through the body. The goal was to gather basic safety information before testing it in people with pulmonary arter…
Phase: PHASE1 • Sponsor: Respira Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC